Key result
Lactoferrin and osteopontin show therapeutic potential for managing cardiometabolic disorders and related complications.
Answers are grounded in this paper and cite their sources.
Milk-derived bioactive proteins have increasingly gained attention and consideration throughout the world due to their high-quality amino acids and multiple health-promoting attributes. Apparently, being at the forefront of functional foods, these bioactive proteins are also suggested as potential alternatives for the management of various complex diseases. In this review, we will focus on lactoferrin (LF) and osteopontin (OPN), two multifunctional dairy proteins, as well as to their naturally occurring bioactive LF-OPN complex. While describing their wide variety of physiological, biochemical, and nutritional functionalities, we will emphasize their specific roles in the perinatal period. Afterwards, we will evaluate their ability to control oxidative stress, inflammation, gut mucosal barrier, and intestinal microbiota in link with cardiometabolic disorders (CMD) (obesity, insulin resistance, dyslipidemia, and hypertension) and associated complications (diabetes and atherosclerosis). This review will not only attempt to highlight the mechanisms of action, but it will critically discuss the potential therapeutic applications of the underlined bioactive proteins in CMD.
No takes yet. Share an insight, caveat, or question.
Lévy et al. (2023) conducted a review in Cardiometabolic disorders (CMD). Lactoferrin (LF), osteopontin (OPN), and LF-OPN complex was evaluated. Lactoferrin, osteopontin, and their complex are highlighted for their potential therapeutic applications in managing cardiometabolic disorders and associated complications.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: